The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Patent Office Rules Against Amgen Humira Challenge

U.S. Patent Office Rules Against Amgen Humira Challenge

January 16, 2016 • By Bill Berkrot

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—U.S. patent officials on Thursday denied petitions by Amgen to review two formulation patents on AbbVie’s Humira (adalimumab), a potential setback in Amgen efforts to market a biosimilar version of the world’s top-selling prescription medicine.

You Might Also Like
  • FDA Panel Backs Amgen Biosimilar of Humira
  • AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
  • FDA Staff Says Amgen Biosimilar ‘Highly Similar’ to AbbVie’s Humira

In June, Amgen, the world’s biggest biotechnology company, asked the U.S. Patent and Trademark Office for the review, arguing that the patents in question should not have been granted in the first place for Humira, an injected rheumatoid arthritis treatment with annual sales approaching $14 billion.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In declining to review the patents, the agency said “we determine, based on the petition and the accompanying evidence, that Amgen has not shown a reasonable likelihood of prevailing on any of its challenges.”

Amgen said it still plans to challenge the legality of the patents.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Although we are disappointed by the PTO’s decision, we continue to question the validity of the patents,” the company said in a statement. “We look forward to presenting our position in court.”

Amgen in November became the first company to file with U.S. health regulators seeking approval to sell a less expensive biosimilar version of the blockbuster medicine. Several companies are also developing biosimilar versions of Humira.

Amgen has said it expects the first of its several biosimilars in development to reach the market between 2017 and 2019.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

AbbVie this week said it sees Humira sales reaching $18 billion by 2020. Based on its various patents, AbbVie said it does not expect competition from biosimilars until 2022.

Unlike chemical medicines, biotech drugs are made from living cells so exact copies are not possible, thus the term biosimilar rather than generic as with copies of pills.

Amgen shares closed up 5.3% at $153.16, while AbbVie shares rose 6.6% to close at $54.56. Shares of both companies were virtually unchanged in extended trading.

Filed Under: Drug Updates, Pharma Co. News Tagged With: adalimumab, Amgen, Biologics & Biosimilars

You Might Also Like:
  • FDA Panel Backs Amgen Biosimilar of Humira
  • AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
  • FDA Staff Says Amgen Biosimilar ‘Highly Similar’ to AbbVie’s Humira
  • Amgen Files for U.S. Approval of Biosimilar

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)